Fidia Farmaceutici enters Italian pediatric market segment
Privately-held Italian drugmaker Fidia Farmaceutici plans to enter the Italian pediatric health care market with the acquisition of the HalyKoo Line developed by the Swiss-based company APR Applied Pharma Research specialized in the development of innovative and patent-protected products (prescription and over-the-counter), that are marketed worldwide
The HalyKoo products will be available in Italy starting next fall: this isthe first complete line of products offering, under only one unique brand, tailor-made therapeutic solutions, designed and developed for children’s health and wellbeing since newborns.
This partnership has enabled Fidia, which is specialized in the R&D and marketing of innovative products based on hyaluronic acid, to officially enter the pediatric market segment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze